Showing results (31-40 of 73) with videos related to
Sort By:
Pageof 8
Pharmacoeconomics|June 30, 2022
Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe ObesityBjörn Schwander, Klaus Kaier, Mickaël Hiligsmann, et al.Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyHelge G Bischoff, David F Heigener, Stefan Walzer, et al.Current Medical Research and Opinion|April 2, 2009
Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspectiveMark Nuijten, Dennis L Andress, Steven E Marx, et al.Human Vaccines & Immunotherapeutics|February 10, 2018
Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian populationStefano Capri, Marco Barbieri, Chiara de Waure, et al.Expert Review of Pharmacoeconomics & Outcomes Research|July 17, 2018
Event simulation and external validation applied in published health economic models for obesity: a systematic reviewBjoern Schwander, Mark Nuijten, Mickaël Hiligsmann, et al.Journal of Medical Economics|April 22, 2018
A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United StatesMark Nuijten, Agnieszka Marczewska, Krysmaru Araujo Torres, et al.Clinical Drug Investigation|March 1, 2015
Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected]Mark Nuijten, Daniela P Roggeri, Alessandro Roggeri, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 16, 2021
A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's PerspectiveMark Nuijten, Livia Dainelli, Bahareh Rasouli, et al.Clinical Drug Investigation|July 1, 2010
Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov modelMark Nuijten, Dennis L Andress, Steven E Marx, et al.Journal of Medical Economics|February 9, 2012
Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in ItalyAlexander Diamantopoulos, Maurizio Benucci, Stefano Capri, et al.Pageof 8